

ArQule Inc (ARQL) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/AD977A65B5BEN.html
Date:	May 30, 2017
Pages:	47
Price:	US\$ 125.00
ID:	AD977A65B5BEN

ArQule Inc (ARQL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ArQule Inc (ArQule) is a development stage clinical biotechnology company. It carries out discovery and development of next-generation, small molecule therapeutics for the treatment of various types of cancer. ArQule develops its oncology product candidates through novel approaches including activated checkpoint therapy platform and c-met survival protein platform. Its lead product candidate, ARQ 197 (tivantinib), an inhibitor of the c-Met receptor tyrosine kinase, is undergoing clinical-stage development. The other product pipeline of the company includes ARQ 087 is a multi-kinase inhibitor, ARQ 092 is an Akt inhibitor, ARQ 751 is a next-generation inhibitor of Akt, ARQ 761 is an activator of the damage response pathway, ARQ 531 is a B-cell malignancies and ARQ 087 is an inhibitor of fibroblast growth factor receptor. ArQule is headquartered in Burlington, Massachusetts, the US.

ArQule Inc Key Recent Developments

May 03,2017: Arqule Reports First Quarter 2017 Financial Results

Mar 07,2017: ArQule Reports Fourth Quarter and Full Year 2016 Financial Results

Nov 07,2016: ArQule Reports Third Quarter 2016 Financial Results
Aug 03,2016: ArQule Reports Second Quarter 2016 Financial Results
May 04,2016: ArQule Reports First Quarter 2016 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

strong>SECTION 1 - ABOUT THE COMPANY

ArQule Inc - Key Facts
ArQule Inc - Key Employees
ArQule Inc - Key Employee Biographies
ArQule Inc - Major Products and Services
ArQule Inc - Pharmaceutical Pipeline Products Data
ArQule Inc, Pipeline Products by Therapy Area
ArQule Inc, Pipeline Products by Development Phase
ArQule Inc - History
ArQule Inc - Company Statement
ArQule Inc - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

ArQule Inc - Business Description
ArQule Inc - SWOT Analysis
SWOT Analysis - Overview
ArQule Inc - Strengths
ArQule Inc - Weaknesses
ArQule Inc - Opportunities
ArQule Inc - Threats
ArQule Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
ArQule Inc, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

May 03, 2017: ArQule Reports First Quarter 2017 Financial Results
Mar 07, 2017: ArQule Reports Fourth Quarter and Full Year 2016 Financial Results
Nov 07, 2016: ArQule Reports Third Quarter 2016 Financial Results
Aug 03, 2016: ArQule Reports Second Quarter 2016 Financial Results
May 04, 2016: ArQule Reports First Quarter 2016 Financial Results
Feb 29, 2016: ArQule Reports Fourth Quarter and Full Year 2015 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

ArQule Inc, Key Facts
ArQule Inc, Key Employees
ArQule Inc, Key Employee Biographies
ArQule Inc, Major Products and Services
ArQule Inc, Number of Pipeline Products by Therapy Area
ArQule Inc, Number of Pipeline Products by Development Stage
ArQule Inc, History
ArQule Inc, Key Competitors
ArQule Inc, Ratios based on current share price

ArQule Inc, Annual Ratios
ArQule Inc, Annual Ratios (Cont.1)
ArQule Inc, Interim Ratios
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
ArQule Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

ArQule Inc, Pipeline Products by Therapy Area
ArQule Inc, Pipeline Products by Development Phase
ArQule Inc, Performance Chart (2012 - 2016)
ArQule Inc, Ratio Charts
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
ArQule Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

GlaxoSmithKline LLC
Eagle Pharmaceuticals Inc
Deciphera Pharmaceuticals LLC
Cytokinetics Inc
Curis Inc
CTI BioPharma Corp
Compugen Ltd
Bristol-Myers Squibb Company
AVEO Pharmaceuticals Inc
Array BioPharma Inc
Ariad Pharmaceuticals Inc

I would like to order:

Product name: ArQule Inc (ARQL) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/AD977A65B5BEN.html>
Product ID: AD977A65B5BEN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/AD977A65B5BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**